Table E1.
Association of asthma therapy with COVID-19–related hospital admission, intensive care unit admission, and hospital mortality among all patients who had a positive SARS-CoV-2 test adjusting for preexisting eosinophilia
| Asthma therapy | n | Hospitalization (adjusted OR [95% CI]) (n = 7,421) | Intensive care unit admission (adjusted OR [95% CI]) (n = 1,638) | Hospital mortality (adjusted OR [95% CI]) (n = 1,431) |
|---|---|---|---|---|
| All patients, n | 43,104 | |||
| No asthma | 35,314 | 1 | 1 | 1 |
| Inactive asthma | 2,681 | 0.91 (0.80-1.04) | 0.79 (0.61-1.04) | 0.69 (0.49-0.97) |
| Active asthma | ||||
| Short-acting β-agonist monotherapy | 3,154 | 1.38 (1.24 1.54) | 1.17 (0.95-1.45) | 0.86 (0.65-1.14) |
| Low-dose iCS | 700 | 1.23 (1.00-1.57) | 0.90 (0.55-1.47) | 0.62 (0.31-1.25) |
| Low-dose iCS-LABA | 657 | 1.10 (0.87-1.38) | 1.13 (0.71-1.80) | 0.70 (0.36-1.31) |
| High-dose iCS-LABA | 321 | 1.57 (1.17-2.13) | 1.34 (0.76-2.36) | 1.34 (0.68-2.64) |
| Triple inhaler therapy | 82 | 2.47 (1.47-4.15) | 1.22 (0.48-3.14) | 1.48 (0.56-3.91) |
CI, confidence interval; iCS, inhaled corticosteroids; LABA, long-acting β-agonist; OR, odds ratio.
Preexisting eosinophilia is defined by a preexisting absolute eosinophil count of >300 cells/μL measured for 15 days or more before the date of a positive SARS-CoV-2 test. Analyses were adjusted for age, sex, race, ethnicity, body mass index, smoking history, pack-years smoking, medications (nonsteroidal anti-inflammatory drugs, angiotensin converting enzyme 2 inhibitor, angiotensin receptor blocker, and intranasal corticosteroids), comorbidities (allergic rhinitis, diabetes, hypertension, coronary artery disease, heart failure, and cancer [historical or current], and immunosuppressive disease), the month of testing, and eosinophilia.